

1 COVID-19 vaccination was a rare potential etiology for cause of death after medicolegal autopsy. A Finnish
2 nationwide study.

3

4 Lasse Pakanen^{1,2,*}, Tuomo Nieminen³, Paula Kuvaja¹, Hanna Nohynek⁴, Sirkka Goebeler⁵, Miia Artama^{4,6},
5 Petteri Hovi⁷

6 ¹ Forensic Medicine Unit, Finnish Institute for Health and Welfare, Oulu

7 ² Department of Forensic Medicine, Research Unit of Biomedicine and Internal Medicine, Medical Research
8 Center Oulu, University of Oulu

9 ³ Information Brokers, Finnish Institute for Health and Welfare, Helsinki

10 ⁴ Infectious Disease Control and Vaccinations, Finnish Institute for Health and Welfare, Helsinki

11 ⁵ Forensic Medicine Unit, Finnish Institute for Health and Welfare, Helsinki

12 ⁶ Faculty of Social Sciences, Epidemiology, Tampere University, Tampere

13 ⁷ Department of Public Health and Welfare, Population Health Unit, Finnish Institute for Health and Welfare,
14 Helsinki

15

16 * Corresponding author. Address: Forensic Medicine Unit, Finnish Institute for Health and Welfare, P.O.

17 Box 310, FI-90101 Oulu, Finland; e-mail: lasse.pakanen@thl.fi; tel.: +358 29 524 7906

18

19 Author contributions: L.P., T.N., P.K., H.N., S.G., and P.H. conceived and designed the study. L.P., P.K. and
20 S.G. conceptualized the gathering of cause-of-death investigation data. T.N., H.N., M.A., and P.H. curated
21 vaccination and risk factor data. L.P., T.N., and P.H. analyzed data, and prepared the manuscript. All authors
22 contributed to interpretation of findings, critical revision of the manuscript, and approved the final version.

23 Data availability: All data generated or analyzed during this study are included in this published article.

24 ABSTRACT

25 COVID-19 vaccinations began globally at the end of 2020. By the end of 2021, 9.8 million doses were given
26 in Finland. Regarding safety, most vaccine-related adverse reactions have been mild, but serious and lethal
27 ones have also occurred. Autopsies in post vaccination deaths may give insight to the extent of fatal health
28 conditions with potential COVID-19 vaccine etiology and provide new hypotheses of possible causalities
29 between vaccination and severe health conditions. We searched the complete documentation on all
30 medicolegal autopsies in Finland between December 2020 and December 2021 to assess how often the basis
31 for autopsy was a suspected fatal adverse reaction to COVID-19 vaccination, and whether vaccination
32 remained a potential etiology for any health condition determined as a cause of death after the autopsy. We
33 linked register-based data on individual COVID-19 vaccination course and pre-existing health conditions.
34 We found 428 autopsy cases with a mention of COVID-19 vaccination, and prior to autopsy, vaccination
35 was suspected to play a part in 76 deaths. Post autopsy, a forensic pathologist considered vaccination as a
36 potential etiology in five underlying and seven contributory causes of death. These included seven
37 thromboembolisms, two diabetic ketoacidoses, one myocarditis, one acute pancreatitis, and one eosinophilic
38 granulomatosis with polyangiitis. In relation to the number of vaccinations within Finland, a suspicion of
39 vaccine-related serious adverse reaction was rarely an indication for medicolegal autopsy. Even less
40 frequently was vaccination considered to play a part in the process leading to death, although considerable
41 doubt remains in the accuracy of individual considerations, and autopsy cannot definitively confirm causality
42 between vaccination and death. Regarding vaccination safety, continuing evaluation of suspected vaccine-
43 related deaths is essential, and an autopsy should be part of the investigation when such a suspicion arises.

44

45 Keywords

46 COVID-19 vaccine, adverse event following immunization, adverse reaction, cause of death, medicolegal
47 autopsy

48 Abbreviations: AEFI, adverse events following immunization; CVST, cerebral venous sinus thrombosis;
49 TTS, thrombosis with thrombocytopenia syndrome; VITT, vaccine-induced immune thrombotic
50 thrombocytopenia

51

52 INTRODUCTION

53 During the COVID-19 pandemic, fast development of vaccines created several products that efficiently
54 prevent severe illness and death caused by the SARS-CoV-2 virus (1). The vaccines were proven to be safe
55 enough to meet the agreed emergency use licensing criteria, and large-scale as well as long-term safety
56 follow-up was to be done only post licensure (2). Post-marketing safety surveillance has revealed rare severe
57 adverse events following immunization (AEFI, terminology used in this paper according to the European
58 Medicines Agency guideline (3), is presented in Table 1), with some considered to be truly caused by the
59 vaccines. The first serious adverse reactions were thromboembolic complications including cerebral venous
60 sinus thrombosis (CVST) and other unusual thrombotic events which were related to adenoviral vector
61 vaccine ChAdOx1 (Vaxzevria, AstraZeneca) as reported by European Medicines Agency in April, 2021 (4).
62 Subsequently, an association emerged between these thromboses and thrombocytopenia, as well as the
63 occurrence of anti-platelet factor 4 antibodies in the patients, and this syndrome was named vaccine-induced
64 immune thrombotic thrombocytopenia (VITT) (5), or thrombosis with thrombocytopenia syndrome (TTS)
65 (6). Notably, VITT is also considered an adverse reaction to another adenoviral vector vaccine,
66 Ad26.COV2.S (COVID-19 Vaccine Janssen, Janssen Group) (5, 7). Additionally, cases of myocarditis and
67 pericarditis have occurred shortly after vaccination, and these conditions have been shown to be associated
68 with mRNA vaccines BNT162b2 (Comirnaty, BioNTech-Pfizer), and mRNA-1273 (Spikevax, Moderna) in
69 several large epidemiological studies, especially in young men (8–10). However, though myocarditis is a
70 severe condition, reports in young men show relatively mild outcomes and no mortality associated with
71 myocarditis shortly after vaccination (11–12). Furthermore, based on a population-based follow-up study of
72 vaccine-related myocarditis, deaths are very rare (13).

73 A vast amount of unconfirmed and misinterpreted data without epidemiological support regarding vaccine-
74 related morbidity and mortality has been of great concern from the beginning of COVID-19 vaccinations
75 (14–15). For an individual who dies within days or weeks following vaccination, the causes of death should
76 be thoroughly examined on one hand because of individual legal protection, and, on the other hand, to reveal
77 potential severe health conditions following immunization. The key investigation in this regard is an autopsy,
78 either medicolegal or clinical. A growing number of autopsy case reports of deaths following COVID-19
79 vaccination have been published (e.g., systematic review by Sessa et al. (16)). However, few larger autopsy-
80 based data have yet been published. The Finnish law requires that a medicolegal cause-of-death investigation
81 must be done when death is considered unexpected, or if it has been caused or suspected to have been caused
82 by non-natural causes such as medical treatment (Act on the Inquest Into the Cause of Death 459/1973).
83 Thus, a medicolegal autopsy is generally instructed by the police when a vaccination is suspected to play a
84 role in the process leading to death.

85 We set out to evaluate how often the basis for medicolegal autopsy was a suspected fatal adverse reaction to
86 COVID-19 vaccination in Finland, and we describe cases in which COVID-19 vaccination remained as a
87 potential etiology for a health condition considered as any cause of death after the autopsy. We also describe
88 those cases in which the forensic pathologist considered COVID-19 vaccination not to have any part in the
89 death process. We describe the medicolegal cause-of-death investigation procedure and discuss the
90 remaining uncertainties in both the accuracy of case-selection for assessment, and in determining the
91 potential vaccine etiology.

92

93 MATERIAL AND METHODS

94

95 *COVID-19 vaccinations in Finland*

96 Since the beginning of the SARS-CoV-2-virus pandemic in 2020, several COVID-19 vaccines have been
97 introduced to the market. In Finland, the first vaccines were given in December 2020. By the end of 2021,

98 9.8 million doses had been administered in the country (17), and nearly 90% of the population aged 12 years
99 or older had received at least one dose (18).

100

101 Initially prioritized groups for COVID-19 vaccinations were the elderly, adults with a risk for severe
102 COVID-19 disease, and health care workers. Vaccination was gradually extended during 2021 to cover the
103 whole adult population with priority by age group from older to younger, and finally to children over five
104 years old. By the end of 2021, five vaccine products had gained conditional marketing authorization:
105 BNT162b2 on Dec 21, 2020; mRNA-1273 on Jan 6, 2021; ChAdOx1 on Jan 29, 2021; Ad26.COV2.S on
106 Mar 11, 2021; and NVX-CoV2373 (Novavax) on Dec 20, 2021 (19). Due to safety concerns
107 related to coagulation disorders, the use of ChAdOx1 ceased on Mar 19, 2021 for those younger than 65
108 years, and altogether on Nov 30, 2021 (20). Because of the suspected relationship of mRNA-1273 and
109 myocarditis and pericarditis, the use of this vaccine ceased for men under 30 years of age on Oct 7, 2021
110 (21). All vaccinations given in Finland are recorded in electronic health record systems and collected to the
111 National Vaccination Register (22).

112

113 *Medicolegal cause-of-death investigation process in suspected vaccine-related deaths in Finland*

114

115 If a suspicion of a relationship between vaccination and death arises, the police instruct a medicolegal
116 autopsy. Suspicions can be based on information from next-of-kin, from treating clinicians, from police
117 investigation and/or in consultation with a forensic pathologist, and they can be fully subjective, based on
118 clinical history, or other circumstances prior to death, e.g. sudden unexpected death close to vaccination with
119 or without a mention of adverse event. The process needs to be actively initiated and the suspicion can be
120 brought forward by any of the mentioned parties. Usually this happens when death occurs close to
121 vaccination, unexpectedly, or when no other obvious cause of death can be determined based on available
122 clinical data. Threshold for initiating the medicolegal process is kept low especially when a relative
123 expresses the suspicion (23). Finland has one of the highest autopsy rates among high income countries (24),

124 with medicolegal autopsies carried out in 13.7% during the study period (Table 2; 25), and the overall
125 autopsy rate being 17.6% of all deaths in 2021 (26).

126 The Finnish Institute for Health and Welfare conducts all medicolegal autopsies in its Forensic Medicine
127 Unit, geographically distributed in five locations covering the whole country. The institute keeps a
128 medicolegal database for all data related to cause-of-death investigation including autopsy reports, death
129 certificates, police reports, and other related documents.

130

131 *Individual assessment of causes of death in medicolegal autopsy*

132

133 Along with a complete macroscopic examination, each autopsy case includes a routine analysis of
134 histological samples. Most cases also include a toxicological analysis to rule out intoxication, or to assess the
135 use of alcohol, narcotics, and medications. Based on individual consideration, the forensic pathologist may
136 request further auxiliary investigations, such as neuropathology, microbiological analyses in suspected
137 infections, or serum tryptase level in suspected anaphylaxis (e.g. 27 for further reference).

138 After all relevant investigations, the forensic pathologist determines the most likely *underlying cause of*
139 *death, intermediate causes of death, the immediate cause of death, and contributory causes of death* to be
140 recorded in death certificate.

141 Causes of death, including statements regarding causality, are always approximations based on a case-by-
142 case assessment and hence involve uncertainty. In a case of suspected vaccine etiology, currently no exact
143 analysis or procedure exists regarding the COVID-19 vaccines in use, upon which a fatal health condition
144 could definitively be determined as to be caused by a vaccine dose given. When assessing vaccination as a
145 potential etiology for any cause of death, the forensic pathologist should consider several questions
146 including, as suggested by the World Health Organization (28): 1) is there strong evidence for other causes;
147 2) is there a known causal association with the vaccine or vaccination; and 3) was the event within the time
148 window of increased risk? Regarding the second and third questions, one must refer to the current, constantly
149 developing scientific knowledge when determining vaccine as an etiology for any given health condition.

150 Likewise, no exact analysis exists upon which vaccination could with certainty be excluded as an etiology
151 for a given health condition. Notably, a forensic pathologist must largely rely on published data, mostly
152 epidemiologic, when assessing the causal connection between vaccination and death.

153

154 *Selection of medicolegal autopsy cases for further examination*

155

156 Data in the medicolegal database are structured and include sex, age, causes of death, the date and location of
157 death, and the personal identification code, which is given to all permanent residents of Finland upon birth or
158 immigration. We examined all medicolegal autopsy cases with both the date of death and the date of autopsy
159 between Dec 26, 2020 (the start of vaccinations in Finland) and Dec 31, 2021 (8,048 autopsy cases). We first
160 excluded cases in which homicide, accident, suicide, or occupational disease was the only grounds for
161 medicolegal autopsy. Then, we also excluded from further evaluation all cases with no mention of having
162 received COVID-19 vaccination in any document recorded in the medicolegal database (police report,
163 autopsy referral, any attached patient records, other related documents, or notably also the autopsy report and
164 death certificate). From among the remaining cases in which vaccination was mentioned, one of the
165 researchers, a forensic pathologist (L.P.), determined, whether an actual suspicion of a relationship between
166 vaccination and death had arisen prior to autopsy based on the recorded data.

167 *Linkage to vaccinations data and risk factors from the national population-wide registers*

168 We linked data between registers and autopsy cases using the personal identification code. We report the sex,
169 age, and vaccination characteristics of the autopsied individuals, along with data from all vaccinated
170 individuals in Finland for comparison. For this purpose, we identified all individuals, whose last known
171 permanent address was in Finland according to the Population Information System, and who received
172 COVID-19 vaccinations according to the Finnish National Vaccination Register between Dec 26, 2020 and
173 Dec 31, 2021 (22). The vaccination register includes the date and vaccine brand of each given COVID-19
174 vaccination.

175 For descriptive purposes, we also linked our cases, along with those COVID-19 vaccinated based on the
176 vaccination register, with data from the care register for health care and the medical reimbursements register
177 on pre-existing risk factors predisposing to severe COVID-19 disease as described in the study of Salo et al.
178 (29). These risk factors, together with age group, were important determinants of the priority and the number
179 of recommended vaccinations for individuals in Finland, and they are also risk factors of death from any
180 cause. These risk factors were: cardiovascular diseases, cognitive disorders, other neurological disorders,
181 diabetes, chronic kidney diseases, chronic liver diseases, pulmonary diseases, immunosuppressive diseases,
182 Addison's disease, schizophrenia, and Down syndrome. Furthermore, data on 24-hour service housing and
183 institutional care were gathered from the same registers. We gathered this risk data starting from Jan 1, 2015
184 until the first vaccine dose, or until death if no record of vaccination was found in the register. Medical
185 reimbursement data was available starting from Jan 1, 2018.

186

187 *Ethics*

188

189 This descriptive study was conducted as part of the Finnish Institute for Health and Welfare's responsibility
190 to monitor the safety of vaccines used in the national vaccination program and to investigate potential
191 adverse events suspected to be linked with vaccination as dictated by the Finnish law (Act on the National
192 Institute for Health and Welfare 668/2008; Government Decree on the National Institute for Health and
193 Welfare 675/2008; and the Communicable Diseases Act 1227/2016). Based on this, Finnish Institute for
194 Health and Welfare has the statutory right, notwithstanding confidentiality provisions, to access necessary
195 information in cause-of-death investigation documents and to link this information with other relevant
196 register data. Accordingly, this study was approved by the Finnish Institute for Health and Welfare's
197 Director of Health Security department, Director of Government Services department, as well as the Deputy
198 Director General of Research, Development and Innovation. The data on the medicolegal autopsies was
199 originally collected according to the Act on Determining the Cause of Death (459/1973).

200

201 RESULTS

202

203 A total of 428 autopsy cases with a mention of having received COVID-19 vaccination were found, and their
204 records were further investigated for the current report by a forensic pathologist (L.P.). A suspicion of
205 vaccine etiology arose in 76 cases prior to autopsy (Figure). After the autopsy and auxiliary investigations,
206 12 cases emerged, in which the forensic pathologist who wrote the death certificate considered the COVID-
207 19 vaccination as a potential etiological factor for any cause of death: in five cases for the underlying cause
208 of death, and in seven cases for a contributory cause of death (Table 3). Three of these cases had no pre-
209 autopsy suspicion of vaccine etiology, and, thus, were not part of the 76 cases (Figure).

210 Details of the vaccinations preceding death existed in the Vaccination register for 417 cases, including all the
211 12 cases with potential vaccine etiology. In further 4 cases, the medicolegal data included a mention of
212 vaccination with details, and in 7 cases, only a mention of vaccination without any details.

213 Most causes of death with potential vaccine etiology (n = 12, see Table 3) were thromboembolic events
214 (7/12) including one VITT with CVST, and one CVST without VITT-association, three cases of pulmonary
215 embolisms, one case of acute myocardial infarction, and one case of recurring cerebral hemorrhage.
216 Furthermore, potential vaccine etiology arose in one case of acute myocarditis, in two cases of diabetic
217 ketoacidosis, in one case of acute pancreatitis, and in one case of eosinophilic granulomatosis with
218 polyangiitis (EGPA). Death occurred within 14 days after vaccination in 7/12 cases. The deaths without a
219 considered vaccine etiology (67/76) were mostly caused by diseases, mainly of cardiovascular origin (Table
220 4).

221 Prior to autopsy, the suspicion of a relationship between vaccination and death came from treating clinicians
222 in 28 (36.8%) cases, a relative in 24 (31.6%) cases, forensic pathologist in 8 (10.5%) cases, and the police in
223 1 (1.3%) case (more than one source was possible in each individual case). Twenty-two (28.9%) cases had a
224 mention of a health condition preceding death suspected to be a vaccine-related (mild) adverse reaction, but
225 no actual suspicion of it causing death was stated. Death occurred at home in 48 (63.2%), in a health care
226 unit in 16 (21.1%), in a social welfare unit in 5 (6.6%), and in other places in 7 (9.2%) cases. As regards the

227 12 cases with potential vaccine etiology, the location of death was home in five cases, health care unit in six
228 cases, and other in one case.

229 The 12 deaths with potential vaccine etiology occurred in all adult age groups and equally in both sexes
230 (Table 5). Half the cases were autopsied in Helsinki, which has proportionally the most autopsies, and all
231 five autopsy locations had at least one case. Four deaths occurred after each first, second, and third dose,
232 while the number of total administered COVID-19 vaccinations were 4.3, 4.1, and 1.3 million, respectively.
233 Ten of the 12 deaths (83%) occurred after vaccination with BNT162b2, which was the vaccine brand with
234 the largest number of vaccinations administered out of all vaccinations (7.9M / 9.8M; 81%). All 12 cases
235 with potential vaccine etiology had one or more chronic health conditions according to the person level
236 register linkage (Table 3): 7/12 (58%) cases had a record of at least one known pre-existing risk factor,
237 which was a larger proportion than with those vaccinated (1.0M / 4.3M; 23%, Table 5). In 8/12 cases,
238 including the remaining five cases without a register record of risk factors, forensic pathologist determined at
239 least one corresponding chronic condition as one of the causes of death after the autopsy.

240

241 DISCUSSION

242

243 In this nationwide analysis, we searched 8,048 medicolegal autopsy reports comprising all medicolegal
244 autopsies in Finland from Dec 26, 2020 to Dec 31, 2021. For comparison, 58,714 deaths from all causes
245 occurred during this time (Table 2; 25), among which were 952 deaths caused by COVID-19 infection in
246 2021 (30). Moreover, 9.8 million COVID-19 vaccinations were given in Finland, and Finnish Institute for
247 Health and Welfare has estimated that the vaccinations prevented more than 7,300 deaths from COVID-19
248 disease and more than 1,000 deaths with COVID-19 disease as a contributory factor in the country by the
249 end of March, 2022 (31). According to our data, 76 cases included a pre-autopsy suspicion of a relationship
250 between COVID-19 vaccination and death, and, after the autopsy, forensic pathologist considered COVID-
251 19 vaccination as a potential etiology for five underlying, and seven contributory causes of death, mainly
252 from thromboembolic causes (7/12). In comparison to the total vaccinated population, the 12 deaths with
253 potential vaccine etiology occurred in both sexes and all adult age groups but included more of those with a

254 third dose and those with known pre-existing risk factors. Due to the remaining uncertainties in catching the
255 right cases, and in considerations about the etiology for the causes of death, the interpretations from the data
256 need to be extremely cautious.

257 To the best of our knowledge, this is the largest published systematic case report series on autopsies
258 conducted in deaths suspected to have COVID-19 vaccine etiology. Most autopsy studies have been single
259 case reports as reviewed by Sessa et al. (16), and a growing number of similar anecdotal reports have been
260 published since. In a Japanese study including 54 cases with death within seven days post vaccination that
261 were autopsied, five cases were concluded to have possible causal relationship between vaccination and
262 death (32). A study from Singapore included 29 autopsy cases from deaths within 72 hours after receiving
263 mRNA-type vaccination, but they did not find any potential causative relationship between vaccination and
264 death in these cases (33). Schneider et al. (34) reported 18 autopsy cases in which death occurred 1–14 days
265 after vaccination in Germany. Of these, five deaths had a potential vaccine etiology including four cases of
266 VITT and one myocarditis (34). Also in Germany, Schwab et al. (35) described 25 autopsy cases with death
267 within 20 days post vaccination, of which five cases died from myocarditis with a potential mRNA-vaccine
268 etiology. Chaves et al. (36) could not find any deaths potentially related to COVID-19 vaccination among the
269 121 autopsies of deceased that had received vaccination in Colombia. In the light of these case series studies,
270 research is needed to reveal to what extent COVID-19 vaccine-related deaths do occur. However, no
271 conclusions can be made on the frequency of potential vaccine-related deaths based on autopsy-studies
272 alone, as the selection criteria for autopsy differ between studies and, more importantly, between countries.

273 In seven of the twelve deaths in our data, forensic pathologist writing the death certificate considered
274 COVID-19 vaccination a potential etiological factor for a diagnosed thromboembolism, which were also the
275 most frequent causes of death considered vaccine-related in previous reports (16). Among these seven cases,
276 only one case of VITT with CVST was identified. Another CVST without thrombocytopenia was also
277 detected. Due to the relatively early cessation of vaccination with ChAdOx1, exposure to this vaccine brand
278 was a minority in Finland (Table 5), which may have limited the occurrence of these potentially lethal
279 adverse reactions. The estimated cumulative 28-day-incidence of VITT has been between 1/26,500 and
280 1/1,000,000 first doses of ChAdOx1 with lower incidences for subsequent doses (5, 37–38). According to

281 See et al. (39), the incidence of VITT after vaccination with Ad26.COV2.S was 1/583,000 doses. The
282 estimated incidence for VITT with CVST after receiving the first dose of ChAdOx1 was 12.3 / 1,000,000
283 when the condition was first recognized as an adverse reaction (40). The rate is clearly higher than the
284 background cumulative 28-day incidence of 0.18 / 1,000,000 (41). Mortality caused by VITT in the
285 COVID-19 vaccinated is unknown, but it is thought to be extremely low (37). However, among patients with
286 diagnosed VITT, the mortality rates have varied 23–73% (5), though with early recognition and adequate
287 care, the prognosis has improved (42). Post vaccination CVST can occur with or without the context of
288 VITT, but with significantly better outcomes, when no thrombocytopenia-association is present (40, 43).

289 Of the seven cases with thromboembolism, three deaths were from pulmonary embolisms, one death from
290 acute myocardial infarction, and one death from recurring cerebral hemorrhage. Deep vein thrombosis and
291 pulmonary embolism are common entities, and the latter is frequently the cause of sudden death in the
292 medicolegal context. Case reports of post vaccination pulmonary embolisms have been published (44), but
293 further population-based studies on ChAdOx (45), and BNT162b2 (46) found no evidence of any increased
294 incidence of pulmonary embolisms after vaccination. However, in a self-controlled case series study in the
295 French population, a slight increase in risk for pulmonary embolism was associated with the first dose of
296 ChAdOx1 (relative incidence 1.41, confidence interval 1.13–1.75) but not with BNT162b2 or mRNA-1273
297 (47). Myocardial infarctions and other acute cardiovascular events are common manifestations in the general
298 population, and they occur after vaccination as well. It has been suggested that COVID-19 vaccination could
299 contribute to cardiovascular events through enhancing prothrombotic state or, unspecifically, as a stress
300 factor (48). As with pulmonary embolism, Botton et al. (47) found an increase in the risk for myocardial
301 infarction after the first dose of ChAdOx1 (relative incidence 1.29, confidence interval 1.11–1.51), and after
302 Ad26.COV2.S (relative incidence 1.75, confidence interval 1.16–2.62), but not with the mRNA-type
303 vaccines. Again, no increased risk for myocardial infarction arose in connection with BNT162b2 in other
304 large study settings as reviewed by Yong et al. (49). Hence, although COVID-19 vaccination was, according
305 to the medicolegal assessment, considered a potential etiological factor for pulmonary embolism in three of
306 our cases and myocardial infarction in one case, all vaccinated with BNT162b2, we found no
307 epidemiological evidence to support these decisions.

308 One case of post vaccination fatal acute myocarditis with potential vaccine etiology was present in our study
309 population in the age group 35 to 64 years. A link between myocarditis and mRNA-type COVID-19 vaccines
310 has been established in large cohort studies (10–11). The highest risk for developing myocarditis has
311 occurred in young men after receiving the second dose (50) Case reports of vaccination-associated
312 myocarditis deaths have been published (35, 51), but, in large study settings, post vaccination myocarditis
313 has rarely been associated with death (8, 10, 13, 50, 52). Notably, myocardial injury associated with a
314 clinical diagnosis of myocarditis after COVID-19 vaccination has been reported mild, as reviewed by Garg
315 et al. (53). In the present study, forensic pathologist considered COVID-19 vaccination as contributory cause
316 of death in two cases with type 1 diabetes mellitus and diabetic ketoacidosis. In one of them, the vaccine was
317 a potential etiological factor for the onset of diabetes, and in the other, it potentially contributed to the
318 worsening of glucose balance in a patient with previously diagnosed diabetes. Many case reports and case
319 series have been published describing post vaccination hyperglycemia, hyperosmolar hyperglycemic
320 syndrome, and diabetic ketoacidosis regardless of the COVID-19 vaccine type as reviewed by Samuel et al.
321 (54). However, we could find only one self-controlled case series analysis regarding acute diabetic
322 complications in patients with type 2 diabetes receiving BNT162b2 (55). According to the study of Wan et
323 al. (55), no ketoacidoses emerged among the 141,224 cases given BNT162b2, and no increased risk for other
324 diabetic complications was observed, either. We did not find any large-scale studies about the effects of
325 COVID-19 vaccines on the onset or on the clinical picture of type 1 diabetes. These kinds of epidemiological
326 studies are warranted, as in some case studies, COVID-19 vaccines were suggested to play a role in the onset
327 of autoimmune diseases, including type 1 diabetes (as reviewed by Chen et al. (56)).

328 Herein, one case of fatal acute pancreatitis emerged with COVID-19 vaccination as its potential etiology. A
329 few case reports about non-fatal post vaccination pancreatitis have been published, mainly concerning
330 BNT162b2 (e.g., 57–58), but we did not find any epidemiological studies addressing the potential
331 association of vaccination and pancreatitis. Lastly, we had one autopsy case who had EGPA, a small-vessel
332 vasculitis, determined as the underlying cause of death, and COVID-19 vaccine considered as potential
333 etiology for the disease. As with pancreatitis, only a few case reports of new onset or relapse of EGPA after
334 COVID-19 vaccination have been published, all regarding mRNA vaccines (59–62). Our findings suggest

335 that further research on the relationship between COVID-19 vaccination and both acute pancreatitis and
336 EGPA is warranted.

337 As we have described in the methods, determining as well as excluding vaccination as an etiology for any
338 cause of death involves a lot of uncertainty, and should be based on epidemiological evidence of association
339 between the vaccination and the adverse event which contributed to the fatality (28). Also, it must be stressed
340 that we only examined the outcomes of the cause-of-death investigation as done by each individual forensic
341 pathologist, and, as such, we did not re-evaluate the possibility of vaccine-etiology in any of the cases. The
342 medicolegal cause-of-death investigation process comprises of gathering information regarding patient
343 history (known diseases, possible symptoms, and findings prior to death) and other circumstances preceding
344 death, as well as examining data received from the autopsy and auxiliary investigations. Based on these, the
345 forensic pathologist generates a most likely scenario including the causes of death and the potential
346 etiologies involved. This scenario is then presented in the autopsy report along with discussion of the
347 uncertainties in each case. It is possible that true vaccine-related deaths were missed, and some of these may
348 even be among the 67 cases in which the forensic pathologist did not consider vaccination as potential
349 etiology. Notably, among these were nine acute myocardial infarctions, five pulmonary embolisms, and one
350 case in which the causes of death could not be determined. However, the lack of epidemiological support
351 (47, 49), and the fact that more plausible etiologies were present (e.g. malignancy in case of pulmonary
352 embolism) argue against a significant proportion of true vaccine-related deaths in our study.

353 Death occurred within 30 days of last vaccination in ten of the twelve cases with vaccination considered as
354 an etiology for a cause of death. We did not examine the interval between vaccination and death in all
355 included autopsies, as some authors have done (32–33, 35). All-cause mortality following COVID-19
356 vaccination has been studied on population level in Finland, and the hazard of death did not increase within
357 63 days of COVID-19 vaccination in Finland (63). Also, a meta-analysis including three self-controlled case
358 series studies totaling 750,000 patients found no association between COVID-19 vaccination and all-cause
359 mortality (64).

360 Because the initiation of the medicolegal process in a suspected vaccine-related death is dependent on a
361 suspicion being brought up, not all cases end up in the hands of forensic pathologist, as seen in the context of

362 iatrogenic deaths (65). This can more often be the case in deaths among elderly people with several chronic
363 illnesses than in deaths deemed more unexpected, as is evident when comparing the medicolegal autopsy
364 rates between 18-34-year-olds (82%) and 65-year-olds and older (9%).

365 Prior to autopsy, the suspicion of the role of COVID-19 vaccine in death was brought forward mostly by
366 treating clinicians. Health care personnel are in a key position in spotting potential iatrogenic deaths, and
367 they are required by law to report such cases to the police in Finland. The systems of investigating suspected
368 iatrogenic deaths differ greatly between countries (66) depending partly on whether it is looked at from the
369 viewpoint of clinical risk management, or whether actual malpractice claims have been raised (23).

370 In many cases, the suspicion of a relationship between COVID-19 vaccine and death was also expressed by
371 the deceased's next of kin, which is in line with today's growing numbers of medical malpractice issues (67).
372 COVID-19 vaccinations have been the topic of extensive public discussions globally, and views
373 discouraging against vaccination on account of alleged hazards have occasionally gained ground (14).
374 Because of this, it is essential to investigate all suspected COVID-19 vaccine-related deaths thoroughly and
375 openly to address these concerns and, if so indicated, maintain the public's confidence in vaccinations.

376

377 *Conclusions*

378 In the context of total vaccinated population and of the number of given vaccine doses, only a few suspicions
379 of vaccine-related deaths arose in the first year of COVID-19 vaccinations in Finland. Even fewer were the
380 number of deaths, in which the forensic pathologist performing the cause-of-death investigation considered
381 vaccine as a potential etiological factor for a cause of death. Although autopsy is a crucial tool in
382 determining the causes of death through detection and documentation of tissue reactions, other settings, such
383 as large epidemiological studies, should be performed to support individual case-assessment. Our study
384 highlights the need for further research related to diabetes, acute pancreatitis and EGPA as potential serious
385 adverse reactions of COVID-19 vaccines. Also, deaths associated with thromboembolic events and
386 myocarditis after vaccination need closer examination. A continuing evaluation of suspected COVID-19
387 vaccine-related deaths is essential in monitoring vaccination safety.

388

389 ACKNOWLEDGEMENTS

390 The authors are grateful to the supporting staff of the Forensic Medicine Unit in gathering data. This study
391 received no specific funding.

392

393 REFERENCES

- 394 1. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19
395 vaccines: a literature review and meta-analysis. *Int J Infect Dis.* 2022;114:252–260. doi:
396 10.1016/j.ijid.2021.11.009.
397
- 398 2. World Health Organization. Covid-19 vaccines: Safety surveillance manual, second edition. Geneva:
399 World Health Organization 2021.
400
- 401 3. European Medicine Agency. Guideline on good pharmacovigilance practices (GVP), Annex I -
402 Definitions (Rev 4). [https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-](https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf)
403 [pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf](https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf). Accessed 21/04/2023.
404
- 405 4. European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very
406 rare cases of unusual blood clots with low blood platelets.
407 [https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-](https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood)
408 [rare-cases-unusual-blood-clots-low-blood](https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood). Accessed 28/01/2023.
409
- 410 5. Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia.
411 *Lancet Haematol.* 2022;9(1):e73-e80. doi: 10.1016/S2352-3026(21)00306-9.
412

- 413 6. European Medicines Agency. EMA raises awareness of clinical care recommendations to manage
414 suspected thrombosis with thrombocytopenia syndrome. [https://www.ema.europa.eu/en/news/ema-](https://www.ema.europa.eu/en/news/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia)
415 [raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia](https://www.ema.europa.eu/en/news/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia).
416 Accessed 15/03/2023.
- 417
- 418 7. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A.
419 Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post
420 COVID-19 vaccination; a systematic review. *J Neurol Sci.* 2021;428:117607. doi:
421 10.1016/j.jns.2021.117607.
- 422
- 423 8. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. *Circulation*
424 2021;144(6):471–484. doi: 10.1161/CIRCULATIONAHA.121.056135.
- 425
- 426 9. Husby A, Hansen JV, Fosbøl E, Thiesson EM, Madsen M, Thomsen RW, Sørensen HT, Andersen
427 M, Wohlfahrt J, Gislason G, Torp-Pedersen C, Køber L, Hviid A. SARS-CoV-2 vaccination and
428 myocarditis or myopericarditis: population based cohort study. *BMJ* 2021;375:e068665. doi:
429 10.1136/bmj-2021-068665.
- 430
- 431 10. Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, Hansen JV, Nohynek H,
432 Gunnes N, Sundström A, Wohlfahrt J, Nieminen TA, Grünewald M, Gulseth HL, Hviid A, Ljung R.
433 SARS-CoV-2 Vaccination and myocarditis in a Nordic cohort study of 23 million residents. *JAMA*
434 *Cardiol.* 2022;7(6):600–612. doi: 10.1001/jamacardio.2022.0583.
- 435
- 436 11. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, Edwards K, Soslow JH, Dendy JM,
437 Schlaudecker E, Lang SM, Barnett ED, Ruberg FL, Smith MJ, Campbell MJ, Lopes RD, Sperling
438 LS, Baumblatt JA, Thompson DL, Marquez PL, Strid P, Woo J, Pugsley R, Reagan-Steiner S,
439 DeStefano F, Shimabukuro TT. Myocarditis cases reported after mRNA-based COVID-19

- 440 vaccination in the US from December 2020 to August 2021. *JAMA*. 2022;327(4):331–340. doi:
441 10.1001/jama.2021.24110.
- 442
- 443 12. Husby A, Køber L. COVID-19 mRNA vaccination and myocarditis or pericarditis. *Lancet*.
444 2022;399(10342):2168–2169. doi: 10.1016/S0140-6736(22)00842-X.
- 445
- 446 13. Husby A, Gulseth HL, Hovi P, Hansen JV, Pihlström N, Gunnes N, Härkänen T, Dahl J, Karlstad Ø,
447 Heliö T, Køber L, Ljung R, Hviid A. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA
448 vaccination in four Nordic countries: population based cohort study. *BMJ Medicine* 2023;2:e000373.
449 doi: 10.1136/bmjmed-2022-000373.
- 450
- 451 14. Pullan S, Dey M. Vaccine hesitancy and anti-vaccination in the time of COVID-19: A Google
452 Trends analysis. *Vaccine*. 2021;39(14):1877–1881. doi: 10.1016/j.vaccine.2021.03.019.
- 453
- 454 15. Gisondi MA, Barber R, Faust JS, Raja A, Strehlow MC, Westafer LM, Gottlieb M. A deadly
455 infodemic: social media and the power of COVID-19 misinformation. *J Med Internet Res*.
456 2022;24(2):e35552. doi: 10.2196/35552.
- 457
- 458 16. Sessa F, Salerno M, Esposito M, Di Nunno N, Zamboni P, Pomara C. Autopsy findings and
459 causality relationship between death and COVID-19 vaccination: a systematic review. *J Clin Med*.
460 2021;10(24):5876. doi: 10.3390/jcm10245876.
- 461
- 462 17. European Centre for Disease Prevention and Control. COVID-19 vaccine tracker.
463 [https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#summary-](https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#summary-tab)
464 [tab](https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#summary-tab). Accessed 28/01/2023.
- 465
- 466 18. Finnish Institute for Health and Welfare. COVID-19 vaccinations in Finland.
467 https://sampo.thl.fi/pivot/prod/en/vaccereg/cov19cov/fact_cov19cov?&row=cov_vac_dose-

468 533170.533164.639082.&row=area-
469 518327.518294.518309.518306.518320.518377.518303.518340.518369.518295.518335.518322.518
470 353.518298.518343.518354.518351.518300.518366.518323.518349.518362.&column=cov_vac_ag
471 e-518413&column=660963L&filter=measure-533185. Accessed 28/01/2023.

472

473 19. Finnish Institute for Health and Welfare. Arranging COVID-19 vaccinations in Finland.
474 [https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-](https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/vaccines-and-coronavirus/arranging-covid-19-vaccinations-in-finland)
475 [updates/vaccines-and-coronavirus/arranging-covid-19-vaccinations-in-finland](https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/vaccines-and-coronavirus/arranging-covid-19-vaccinations-in-finland). Accessed
476 28/01/2023.

477

478 20. Finnish Institute for Health and Welfare. Koronarokotusten järjestäminen Suomessa [Finnish].
479 [https://thl.fi/fi/web/infektioaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-](https://thl.fi/fi/web/infektioaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-19/rokotteet-ja-koronavirus/koronarokotusten-jarjestaminen-suomessa)
480 [19/rokotteet-ja-koronavirus/koronarokotusten-jarjestaminen-suomessa](https://thl.fi/fi/web/infektioaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-19/rokotteet-ja-koronavirus/koronarokotusten-jarjestaminen-suomessa). Accessed 16/02/2023.

481

482 21. Finnish Institute for Health and Welfare. THL issues instructions that men under 30 years of age
483 should only be offered the Comirnaty coronavirus vaccine. [https://thl.fi/en/web/thlfi-en/-/thl-issues-](https://thl.fi/en/web/thlfi-en/-/thl-issues-instructions-that-men-under-30-years-of-age-should-only-be-offered-the-comirnaty-coronavirus-vaccine)
484 [instructions-that-men-under-30-years-of-age-should-only-be-offered-the-comirnaty-coronavirus-](https://thl.fi/en/web/thlfi-en/-/thl-issues-instructions-that-men-under-30-years-of-age-should-only-be-offered-the-comirnaty-coronavirus-vaccine)
485 [vaccine](https://thl.fi/en/web/thlfi-en/-/thl-issues-instructions-that-men-under-30-years-of-age-should-only-be-offered-the-comirnaty-coronavirus-vaccine). Accessed 28/01/2023.

486

487 22. Baum U, Sundman J, Jääskeläinen S, Nohynek H, Puumalainen T, Jokinen J. Establishing and
488 maintaining the National Vaccination Register in Finland. *Euro Surveill.* 2017;22(17):30520. doi:
489 10.2807/1560-7917.ES.2017.22.17.30520.

490

491 23. Pakanen L, Keinänen N, Kuvaja P. Presumed adverse events in health care are a frequent indication
492 for medico-legal autopsy in Finland. *Forensic Sci Med Pathol.* 2020;16(1):65–70. doi:
493 10.1007/s12024-019-00193-4.

494

- 495 24. Lunetta P, Lounamaa A, Sihvonen S. Surveillance of injury-related deaths: medicolegal autopsy
496 rates and trends in Finland. *Inj Prev*. 2007;13(4):282–4. doi: 10.1136/ip.2006.012922.
497
- 498 25. Official Statistics of Finland. Deaths. ISSN=1798-2545. Helsinki: Statistics Finland.
499
- 500 26. Statistics Finland. 11c1 -- Autopsies and other means to determine cause of death by age and sex of
501 deceased, 1975–2021.
502 https://pxdata.stat.fi/PxWeb/pxweb/en/StatFin/StatFin__ksyyt/statfin_ksyyt_pxt_11c1.px/. Accessed
503 28/01/2023.m
504
- 505 27. Madea B, ed. Handbook of forensic medicine. Wiley-Blackwell: Hoboken, NJ. 2014.
506
- 507 28. World Health Organization. Causality assessment of an adverse event following immunization
508 (AEFI): user manual for the revised WHO classification, 2nd ed. World Health Organization,
509 Geneva, Switzerland. <https://apps.who.int/iris/handle/10665/259959>. Accessed 28/01/2023.
510
- 511 29. Salo H, Lehtonen T, Auranen K, Baum U, Leino T. Predictors of hospitalisation and death due to
512 SARS-CoV-2 infection in Finland: A population-based register study with implications to
513 vaccinations. *Vaccine*. 2022;40(24):3345–3355. doi: 10.1016/j.vaccine.2022.04.055.
514
- 515 30. Statistics Finland. Causes of death. Reference period: 2021. Helsinki: Statistics Finland.
516 <https://www.stat.fi/en/publication/cktdxrx6o4sv90b62jy6t7qbg>. Accessed 28/01/2023.
517
- 518 31. Finnish Institute for Health and Welfare. Study: Coronavirus vaccines prevented around 7,300
519 deaths due to COVID-19 in Finland by the end of March 2022. [https://thl.fi/en/web/thlfi-en/-/study-](https://thl.fi/en/web/thlfi-en/-/study-coronavirus-vaccines-prevented-around-7-300-deaths-due-to-covid-19-in-finland-by-the-end-of-march-2022)
520 [coronavirus-vaccines-prevented-around-7-300-deaths-due-to-covid-19-in-finland-by-the-end-of-](https://thl.fi/en/web/thlfi-en/-/study-coronavirus-vaccines-prevented-around-7-300-deaths-due-to-covid-19-in-finland-by-the-end-of-march-2022)
521 [march-2022](https://thl.fi/en/web/thlfi-en/-/study-coronavirus-vaccines-prevented-around-7-300-deaths-due-to-covid-19-in-finland-by-the-end-of-march-2022). Accessed 28/01/2023.
522

- 523 32. Suzuki H, Ro A, Takada A, Saito K, Hayashi K. Autopsy findings of post-COVID-19 vaccination
524 deaths in Tokyo Metropolis, Japan, 2021. *Leg Med.* 2022;59:102134. doi:
525 10.1016/j.legalmed.2022.102134.
526
- 527 33. Yeo A, Kuek B, Lau M, Tan SR, Chan S. Post COVID-19 vaccine deaths - Singapore's early
528 experience. *Forensic Sci Int.* 2022;332:111199. doi: 10.1016/j.forsciint.2022.111199.
529
- 530 34. Schneider J, Sottmann L, Greinacher A, Hagen M, Kasper H-U, Kuhnen C, Schlepper S, Schmidt S,
531 Schulz R, Thiele T, Thomas C, Schmeling A. Postmortem investigation of fatalities following
532 vaccination with COVID-19 vaccines. *Int J Legal Med.* 2021;135(6):2335–2345. doi:
533 10.1007/s00414-021-02706-9.
534
- 535 35. Schwab C, Domke LM, Hartmann L, Stenzinger A, Longerich T, Schirmacher P. Autopsy-based
536 histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination. *Clin Res*
537 *Cardiol.* 2023;112(3):431–440. doi: 10.1007/s00392-022-02129-5.
538
- 539 36. Chaves JJ, Bonilla JC, Chaves-Cabezas V, Castro A, Polo JF, Mendoza O, Correa-Rodríguez J,
540 Piedrahita AC, Romero-Fandiño IA, Caro MV, González AC, Sánchez LK, Murcia F, Márquez G,
541 Benavides A, Quiroga MDP, López J, Parra-Medina R. A postmortem study of patients vaccinated
542 for SARS-CoV-2 in Colombia. *Rev Esp Patol.* 2023;56(1):4–9. doi: 10.1016/j.patol.2022.09.003.
543
- 544 37. Aleem A, Nadeem AJ. Coronavirus (COVID-19) vaccine-induced immune thrombotic
545 thrombocytopenia (VITT). 2. In: *StatPearls [Internet]*. StatPearls Publishing: Treasure Island, FL.
546 2022.
547
- 548 38. Pai M. Epidemiology of VITT. *Semin Hematol.* 2022;59(2):72–75. doi:
549 10.1053/j.seminhematol.2022.02.002.
550

- 551 39. See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP,
552 Beavers SF, Durbin AP, Edwards K, Miller E, Harrington TA, Mba-Jonas A, Nair N, Nguyen DT,
553 Talaat KR, Urrutia VC, Walker SC, Creech CB, Clark TA, DeStefano F, Broder KR. US case reports
554 of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March
555 2 to April 21, 2021. *JAMA*. 2021;325(24):2448–2456. doi: 10.1001/jama.2021.7517.
556
- 557 40. Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, Yeo JM, Zhang L,
558 Hassan-Smith G, Jones M, Hutchcroft C, Hobson E, Warcel D, White D, Ferdinand P, Webb A,
559 Solomon T, Scully M, Werring DJ, Roffe C, CVT After Immunisation Against COVID-19 (CAIAC)
560 collaborators. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a
561 multicentre cohort study. *Lancet*. 2021;398(10306):1147–1156. doi: 10.1016/S0140-6736(21)01608-
562 1.
563
- 564 41. Hovi P, Palmu AA, Nieminen TA, Artama M, Jokinen J, Ruokokoski E, Lassila R, Nohynek H,
565 Kilpi T. Incidence of sinus thrombosis with thrombocytopenia-A nation-wide register study. *PLoS*
566 *One*. 2023;18(2):e0282226. doi: 10.1371/journal.pone.0282226.
567
- 568 42. van de Munckhof A, Krzywicka K, Aguiar de Sousa D, Sánchez van Kammen M, Heldner MR, Jood
569 K, Lindgren E, Tatlisumak T, Putaala J, Kremer Hovinga JA, Middeldorp S, Levi M, Arnold M,
570 Ferro JM, Coutinho JM. Declining mortality of cerebral venous sinus thrombosis with
571 thrombocytopenia after SARS-CoV-2 vaccination. *Eur J Neurol*. 2022;29(1):339–344. doi:
572 10.1111/ene.15113.
573
- 574 43. Sánchez van Kammen M, Aguiar de Sousa D, Poli S, Cordonnier C, Heldner MR, van de Munckhof
575 A, Krzywicka K, van Haaps T, Ciccone A, Middeldorp S, Levi MM, Kremer Hovinga JA, Silvis S,
576 Hiltunen S, Mansour M, Arauz A, Barboza MA, Field TS, Tsivgoulis G, Nagel S, Lindgren E,
577 Tatlisumak T, Jood K, Putaala J, Ferro JM, Arnold M, Coutinho JM; Cerebral Venous Sinus
578 Thrombosis With Thrombocytopenia Syndrome Study Group; Sharma AR, Elkady A, Negro A,

- 579 Günther A, Gutschalk A, Schönenberger S, Buture A, Murphy S, Paiva Nunes A, Tiede A,
580 Puthuppallil Philip A, Mengel A, Medina A, Hellström Vogel Å, Tawa A, Aujayeb A, Casolla B,
581 Buck B, Zanferrari C, Garcia-Esperon C, Vayne C, Legault C, Pfrepper C, Tracol C, Soriano C,
582 Guisado-Alonso D, Bougon D, Zimatore DS, Michalski D, Blacquièrè D, Johansson E, Cuadrado-
583 Godia E, De Maistre E, Carrera E, Vuillier F, Bonneville F, Giammello F, Bode FJ, Zimmerman J,
584 d'Onofrio F, Grillo F, Cotton F, Caparros F, Puy L, Maier F, Gulli G, Frisullo G, Polkinghorne G,
585 Franchineau G, Cangür H, Katzberg H, Sibon I, Baharoglu I, Brar J, Payen JF, Burrow J, Fernandes
586 J, Schouten J, Althaus K, Garambois K, Derex L, Humbertjean L, Lebrato Hernandez L, Kellermair
587 L, Morin Martin M, Petruzzellis M, Cotelli M, Dubois MC, Carvalho M, Wittstock M, Miranda M,
588 Skjelland M, Bandettini di Poggio M, Scholz MJ, Raposo N, Kahnis R, Kruyt N, Huet O, Sharma P,
589 Candelaresi P, Reiner P, Vieira R, Acampora R, Kern R, Leker R, Coutts S, Bal S, Sharma SS,
590 Susen S, Cox T, Geeraerts T, Gattringer T, Bartsch T, Kleinig TJ, Dizonno V, Arslan Y.
591 Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2
592 vaccine-induced immune thrombotic thrombocytopenia. *JAMA Neurol.* 2021;78(11):1314–1323.
593 doi: 10.1001/jamaneurol.2021.3619.
- 594
- 595 44. Ifeanyi N, Chinenye N, Oladiran O, David E, Mmonu C, Ogbonna-Nwosu C. Isolated pulmonary
596 embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary
597 embolism complications and follow-up. *J Community Hosp Intern Med Perspect.* 2021;11(6):877–
598 879. doi: 10.1080/20009666.2021.1990825.
- 599
- 600 45. Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and
601 the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? *Lancet.*
602 2021;397(10283):1441–1443. doi: 10.1016/S0140-6736(21)00762-5.
- 603
- 604 46. Jabagi MJ, Botton J, Bertrand M, Weill A, Farrington P, Zureik M, Dray-Spira R. Myocardial
605 infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people
606 aged 75 years or older. *JAMA.* 2022;327(1):80–82. doi: 10.1001/jama.2021.21699.

607

608 47. Botton J, Jabagi MJ, Bertrand M, Baricault B, Drouin J, Le Vu S, Weill A, Farrington P, Zureik M,
609 Dray-Spira R. Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-
610 19 vaccines in adults younger than 75 years in France. *Ann Intern Med.* 2022;175(9):1250–1257.
611 doi: 10.7326/M22-0988.

612

613 48. Aye YN, Mai AS, Zhang A, Lim OZH, Lin N, Ng CH, Chan MY, Yip J, Loh PH, Chew NWS.
614 Acute myocardial infarction and myocarditis following COVID-19 vaccination. *QJM.*
615 2021;hcab252. doi: 10.1093/qjmed/hcab252.

616

617 49. Yong SJ, Halim A, Halim M, Al Mutair A, Alhumaid S, Al-Sihati J, Albayat H, Alsaeed M, Garout
618 M, Al Azmi R, Aldakheel N, Alshukairi AN, Al Ali HA, Almoumen AA, Rabaan AA. Rare adverse
619 events associated with BNT162b2 mRNA vaccine (Pfizer-BioNTech): a review of large-scale,
620 controlled surveillance studies. *Vaccines.* 2022;10(7):1067. doi: 10.3390/vaccines10071067.

621

622 50. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, Olsha-Castell S, Arad D, Hasin T,
623 Levi N, Asleh R, Amir O, Meir K, Cohen D, Dichtiar R, Novick D, HersHKovitz Y, Dagan R,
624 Leitersdorf I, Ben-Ami R, Miskin I, Saliba W, Muhsen K, Levi Y, Green MS, Keinan-Boker L,
625 Alroy-Preis S. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. *N Engl J*
626 *Med.* 2021;385(23):2140–2149. doi: 10.1056/NEJMoa2109730.

627

628 51. Choi S, Lee S, Seo J-W, Kim M-J, Jeon YH, Park JH, Lee JK, Yeo NS. Myocarditis-induced Sudden
629 Death after BNT162b2 mRNA COVID-19 vaccination in Korea: Case report focusing on
630 histopathological findings. *J Korean Med Sci.* 2021 Oct 18;36(40):e286. doi:
631 10.3346/jkms.2021.36.e286.

632

633 52. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K,
634 Harnden A, Coupland CAC, Channon KM, Mills NL, Sheikh A, Hippisley-Cox J. Risks of

- 635 myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-
636 CoV-2 infection. *Nat Med.* 2022;28(2):410–422. doi: 10.1038/s41591-021-01630-0.
- 637
- 638 53. Garg R, Hussain M, Friedrich MG. Phenotyping myocardial injury related to COVID and SARS-
639 CoV-2 vaccination: insights from cardiovascular magnetic resonance. *Front Cardiovasc Med.*
640 2023;10:1186556. doi: 10.3389/fcvm.2023.1186556.
- 641
- 642 54. Samuel SM, Varghese E, Triggler CR, Büsselberg D. COVID-19 vaccines and hyperglycemia-is
643 there a need for postvaccination surveillance? *Vaccines.* 2022;10(3):454. doi:
644 10.3390/vaccines10030454.
- 645
- 646 55. Wan EYF, Chui CSL, Mok AHY, Xu W, Yan VKC, Lai FTT, Li X, Wong CKH, Chan EWY, Lui
647 DTW, Tan KCB, Hung IFN, Lam CLK, Leung GM, Wong ICK. mRNA (BNT162b2) and
648 inactivated (CoronaVac) COVID-19 vaccination and risk of adverse events and acute diabetic
649 complications in patients with type 2 diabetes mellitus: a population-based study. *Drug Saf.*
650 2022;45(12):1477–1490. doi: 10.1007/s40264-022-01228-6.
- 651
- 652 56. Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, Pan HF. New-onset autoimmune phenomena
653 post-COVID-19 vaccination. *Immunology.* 2022;165(4):386–401. doi: 10.1111/imm.13443.
- 654
- 655 57. Cacadac R, Jamali A, Jamali R, Nemovi K, Vosoughi K, Bayraktar Z. Acute pancreatitis as an
656 adverse effect of COVID-19 vaccination. *SAGE Open Med Case Rep.*
657 2022;10:2050313X221131169. doi: 10.1177/2050313X221131169.
- 658
- 659 58. Kalra RK, Jayadeep S, Ball AL. Acute pancreatitis in an adolescent following COVID vaccination.
660 *Clin Pediatr.* 2022;61(3):236–240. doi: 10.1177/00099228211067678.
- 661

- 662 59. Costanzo G, Ledda AG, Ghisu A, Vacca M, Firinu D, Del Giacco S. Eosinophilic granulomatosis
663 with polyangiitis relapse after COVID-19 vaccination: a case report. *Vaccines*. 2021;10(1):13. doi:
664 10.3390/vaccines10010013.
- 665
- 666 60. Chan-Chung C, Ong CS, Chan LL, Tan EK. Eosinophilic granulomatosis with polyangiitis after
667 COVID-19 vaccination. *QJM*. 2022;114(11):807–809. doi: 10.1093/qjmed/hcab273.
- 668
- 669 61. Ibrahim H, Alkhatib A, Meysami A. Eosinophilic granulomatosis with polyangiitis diagnosed in an
670 elderly female after the second dose of mRNA vaccine against COVID-19. *Cureus*.
671 2022;14(1):e21176. doi: 10.7759/cureus.21176.
- 672
- 673 62. Nappi E, De Santis M, Paoletti G, Pelaia C, Terenghi F, Pini D, Ciccarelli M, Selmi CF, Puggioni F,
674 Canonica GW, Heffler E. New onset of eosinophilic granulomatosis with polyangiitis following
675 mRNA-based COVID-19 vaccine. *Vaccines*. 2022;10(5):716. doi: 10.3390/vaccines10050716.
- 676
- 677 63. Nieminen T, Hovi P, Härkänen T, Kaukonen M, Nohynek H. Kuolleisuus välittömästi
678 koronarokottamisen jälkeen : Koronarokotusten turvallisuus Suomessa [Finnish] [Hazard of death
679 immediately following COVID-19 vaccination]. Finnish Institute for Health and Welfare (THL),
680 Helsinki, Finland. <https://urn.fi/URN:ISBN:978-952-343-981-8>. Accessed 15/09/2023.
- 681
- 682 64. Marchand G, Masoud AT, Medi S. Risk of all-cause and cardiac-related mortality after vaccination
683 against COVID-19: A meta-analysis of self-controlled case series studies. *Hum Vaccin Immunother*.
684 2023;19(2):2230828. doi: 10.1080/21645515.2023.2230828.
- 685
- 686 65. Kuvaja P, Keinänen N, Pakanen L. The incidence of iatrogenic deaths in the Finnish cause-of-death
687 statistics; a retrospective study. *J Forensic Leg Med*. 2022 Feb;86:102302. doi:
688 10.1016/j.jflm.2021.102302.
- 689

- 690 66. Ferrara SD, Baccino E, Bajanowski T, Boscolo-Berto R, Castellano M, De Angel R, Pauliukevičius
691 A, Ricci P, Vanezis P, Vieira DN, Viel G, Villanueva E; EALM Working Group on Medical
692 Malpractice. Malpractice and medical liability. European guidelines on methods of ascertainment
693 and criteria of evaluation. *Int J Legal Med.* 2013;127(3):545–557. doi: 10.1007/s00414-013-0836-5.
694
- 695 67. Ferrara SD. Medical malpractice and legal medicine. *Int J Legal Med.* 2013;127(3):541–543. doi:
696 10.1007/s00414-013-0839-2.

697

698

699

700 FIGURE LEGENDS

701

702 **Figure.** Flow chart presenting the selection of autopsy cases. Vaccination data was obtained from Finnish
703 National Vaccination Register.

704

705 CONFLICT OF INTEREST

706 L.P. is a former small shareholder of AstraZeneca. H.N. is a member of the National Immunization
707 Technical Advisory Group of Finnish Institute for Health and Welfare (THL). H.N. is chair of the WHO
708 Strategic Advisory Group of Experts. THL has until 9/2022 conducted Public-Private Partnerships with
709 vaccine manufacturers and has previously received research funding for studies unrelated to COVID-19 from
710 GlaxoSmithKline Vaccines, Pfizer, and Sanofi Pasteur (including T.N. as an investigator). All other authors
711 declare no financial or non-financial competing interests.

712

713

714 **TABLES**

715 **Table 1. Definitions of vaccine-related incidents used in this paper.**

Term	Definition
Adverse event following immunization (AEFI)	Any health condition or problem that occurs following immunization and which does not necessarily have a causal relationship with vaccination (3)
(Serious) adverse reaction	Noxious and unintended health condition in response to vaccination with a suspected causal relationship. Serious adverse reactions include health conditions which are life-threatening or result in death (3).
Unrelated health problems following vaccination	Health condition considered not to be caused by vaccine
Cause of death	Cause of death as stated in the death certificate determined by a forensic pathologist or another physician

716

717

718

719 **Table 2. Medicolegal autopsies carried out in relation to total death during the study period, Dec 26,**
720 **2020 – Dec 31, 2021.**

	Medicolegal autopsies	Total deaths (25)	Autopsy-percentage
End of follow-up	Dec 31, 2021	Dec 31, 2021	
Number of cases	8,048	58,714	13.7
Sex			
Men	5,597	29,697	18.9
Women	2,451	29,017	8.5
Age, years			
< 18	80	214	37.4
18–34	531	646	82.2
35–64	2,751	6,862	40.1
≥ 65	4,686	50,992	9.2

721

722 **Table 3. Details of all cases in Finland in which a forensic pathologist considered a cause of death to**
 723 **have COVID-19 vaccine etiology.**

Cause of death considered to have vaccine etiology¹	Brand of last vaccine dose	Days between vaccination and death²	Age group	Predisposing risk factors (register data)³	Other causes of death¹
VITT with CVST (U)	ChAdOx1	11	35–64	Diabetes, neurological condition	-
CVST without VITT-association (U)	BNT162b2	40	18–34	-	Coagulation disorder (C), morbid obesity (C)
Acute myocarditis (U)	BNT162b2	4	35–64	-	Coronary artery disease (C), alcohol use (C)
Acute pancreatitis (U)	BNT162b2	3	35–64	Cardiovascular disease, immunosuppressive diseases, pulmonary diseases	-
Contribution to pulmonary embolism (C)	BNT162b2	10	≥65	Cardiovascular diseases, Cognitive disorders, 24-hour service housing	Cognitive disorder (U), pneumonia (I), coronary artery disease (C), sequelae of cerebral infarction (C), pulmonary embolism (C)
Contribution to	BNT162b2	24	≥65	Cardiovascular	Pulmonary embolism

pulmonary embolism (C)				disease	(U)
Contribution to pulmonary embolism (C)	BNT162b2	27	≥65	Immunosuppressive diseases	Myocardial hypertrophy (U), deep vein thrombosis (INT), pulmonary embolism (I)
Eosinophilic granulomatosis with polyangiitis (U)	BNT162b2	170 ²	35–64	Pulmonary diseases	Pulmonary embolism (I)
Worsening of glucose balance, ketoacidosis (C)	ChAdOx1	6	35–64	Diabetes, immunosuppressive diseases, Addison’s disease	Type 1 diabetes (U), coronary artery disease (C)
Onset of diabetes, ketoacidosis (C)	BNT162b2	17	18–34	-	Type 1 diabetes (U), cerebral oedema (I), pneumonia (C)
Contribution to recurring cerebral hemorrhage (C)	BNT162b2	12	≥65	-	Cerebral amyloid angiopathy (U), intracerebral hemorrhage (INT), pneumonia (I)
Contribution to myocardial infarction (C)	BNT162b2	9	≥65	-	Coronary artery disease (U), myocardial infarction (I)

724 ¹Cause of death was U = underlying, INT = intermediate, I = immediate, or C = contributory.

725 ²Note that this is the delay from vaccination to death. The delay from vaccination to onset of the health
726 condition is not included in the research data.

727 ³Note that the risk factor data were originally collected for population-level analyses and may not be
728 conclusive on individual level.

729 CVST, cerebral venous sinus thrombosis; VITT, vaccine-induced immune thrombotic thrombocytopenia

730

731

732 **Table 4. Causes of death in cases with suspected relationship between COVID-19 vaccination and**
 733 **death prior to autopsy but with no vaccine etiology considered after medicolegal autopsy.**

Cause of death	Number of cases (%)
Disease	62 (92.5)
Cardiovascular diseases	43 (64.2)
• Acute myocardial infarction	9 (13.4)
• Arrhythmia	1 (1.5)
• Other / unknown mechanism	33 (49.3)
Cerebrovascular diseases	2 (3.0)
Alcohol-related diseases	1 (1.5)
Gastroenterological diseases	3 (4.5)
Malignancies	2 (3.0)
Pulmonary embolism	5 (7.5)
Pulmonary diseases	2 (3.0)
Endocrinopathies and nutritional diseases	2 (3.0)
Neurodegenerative diseases and dementia	2 (3.0)
Accident	4 (6.0)
Undetermined	1 (1.5)
Total	67 (100.0)

734

735 **Table 5. Data on demographics, vaccinations, and pre-existing health conditions.**

	COVID-19 vaccine considered as etiology for any cause of death after medicolegal autopsy	Suspicion of a relationship between COVID-19 vaccine and death prior to medicolegal autopsy	Exposed population
End of follow-up	Death	Death	Dec 31, 2021 ¹
Number of cases	12	76	4,345,346
Sex			
Men	6	34	2,100,677
Women	6	42	2,244,669
Age, years			
< 18	0	0	323,599
18–34	2	4	930,650
35–64	5	23	1,888,942
≥ 65	5	49	1,202,155
Most recent vaccine dose of the deceased vs. population vaccinated with cumulative number of doses			
1	4	45	4,345,346
2	4	19	4,135,987
3	4	9	1,265,677
4	0	0	3,042
Vaccinations			

ChAdOx1	2	19	553,426
BNT162b2	10	46	7,909,387
mRNA-1273	0	8	1,285,369
Ad26.COV2.S	0	1	206
Other	0	0	1,664
Total			9,750,052
Number of pre-existing risk factors ²			
0	5	19	3,328,945
1	3	15	804,011
2	2	17	176,518
≥3	2	25	35,872
Nursing home residency	0	1	28,763
Need for 24-hour care	1	10	65,532
¹ Date for calculating age at first dose. ² Pre-existing risk factors up until the first given vaccine dose, (each as 0 or 1): cardiovascular diseases, cognitive disorders, other neurological disorders, diabetes, chronic kidney diseases, chronic liver diseases, pulmonary diseases, immunosuppressive diseases, Addison’s disease, schizophrenia, and Down syndrome			

736

737

738

739

